New keytruda copycat tested in lung cancer patients after surgery
NCT ID NCT07180862
First seen Jun 27, 2026 · Last updated Jul 17, 2026 · Updated 1 time
Summary
This study compares a new drug, BAT3306, to the approved drug Keytruda in people with stage IB-IIIA non-small cell lung cancer whose tumors have been completely removed by surgery. The goal is to see if BAT3306 works similarly as an additional treatment to help keep the cancer from coming back. About 140 adults aged 18 to 75 will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital Tongji Medical College Huazhong University of Science & Technology
RECRUITINGWuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immunotherapy be safely used in early lung cancer? a Real-World study investigates
- Can an oral chemo pill boost immunotherapy's power against lung cancer?
- Can an immunotherapy cocktail shrink inoperable lung tumors?
- Immunotherapy boosts radiation against early lung cancer
- Lab-Grown lung tumors could reveal why some drugs work and others fail
- AI-Powered navigation aims to pinpoint tiny lung nodules during surgery